Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenerelle is a biotechnology company specializing in the development and manufacture of high-potency regenerative biologics derived from human umbilical cord tissue. The company focuses on harnessing the power of the secretome, including exosomes and growth factors, to promote tissue repair and modulate inflammatory responses. Their product line is primarily designed for applications in orthopedics, wound care, and medical aesthetics. Regenerelle operates state-of-the-art manufacturing processes to ensure the purity and efficacy of its acellular stem cell-derived products. By providing concentrated regenerative factors, the company aims to offer effective alternatives to traditional whole-cell therapies while minimizing immunogenic risks.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regenerelle Stem Cells.